Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 26:27:e54452.
doi: 10.2196/54452.

Using Virtual Reality to Improve Outcomes Related to Quality of Life Among Older Adults With Serious Illnesses: Systematic Review of Randomized Controlled Trials

Affiliations

Using Virtual Reality to Improve Outcomes Related to Quality of Life Among Older Adults With Serious Illnesses: Systematic Review of Randomized Controlled Trials

Bhagvat Maheta et al. J Med Internet Res. .

Abstract

Background: Virtual reality (VR) has promise as an innovative nonpharmacologic treatment for improving a patient's quality of life. VR can be used as an adjunct or treatment for many acute and chronic conditions, including serious illnesses.

Objective: This systematic review aims to assess the current state of the literature of randomized controlled trials that use VR in patients with serious illnesses. Two secondary aims include assessing intervention components associated with improved quality of life and functional outcomes among older adults, as well as evaluating how well the randomized controlled trials adhere to consensus standards for VR research.

Methods: We searched PubMed, Embase, and CINAHL for randomized controlled studies published at any time. We screened and accepted studies that reported outcomes related to patients' quality of life, provided an immersive VR intervention, and included patients with serious illness. We narratively summarized key attributes of publications that shed light on study efficacy, generalizability, replicability, and clinical utility. All studies were assessed for study quality with the Cochrane Risk of Bias tool and for concordance with 8 recent consensus standards for VR research.

Results: From the 12,621 articles searched in May 2024, a total of 24 (0.19%) studies met the inclusion criteria, and of these, 88% (21/24) reported an improvement in at least 1 patient quality of life outcome and 67% (16/24) had a high risk of bias. In 7 (n=24, 29%) studies, VR was used to provide distraction therapy to reduce pain. In total, 5 (n=24, 21%) studies included training, supervision, and assistance in VR use, which demonstrated improvements in patient quality of life-related outcomes. Of 24 studies, 9 (38%) included patients with stroke, 9 (38%) included patients with cancer, 4 (17%) included patients with cardiovascular disease, 1 (4%) included patients with chronic obstructive pulmonary disease, and 1 (4%) included patients who reported pain in hospital. In all 9 studies that included patients with stroke, the main purpose of VR was to improve mobility and strength; these studies had higher frequency and longer durations of VR use, ranging from 2 to 9 weeks, as compared to a VR use duration of <2 weeks for studies aiming to reduce pain or anxiety. Regarding consensus standards for VR research, 29% (7/24) of the studies adhered to all 8 criteria, and all studies (24/24, 100%) adhered to ≥5 criteria.

Conclusions: Nascent evidence suggests VR's potential in mitigating pain, anxiety, and depression and improving mobility among persons with serious illnesses. Most studies did not provide detailed information about unassisted or assisted use, suggesting that VR for older adults is currently most appropriate for observed settings with assistance available.

Trial registration: PROSPERO CRD42022346178; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=346178.

Keywords: anxiety; hospice; older adults; pain; palliative care; patient outcomes; serious illness; systematic review; virtual reality.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Author TO contributed to the project while working at the VA, however, is now employed at Microsoft. After his participation in the project, he also recently became an advisor for the VR enabled company RadiusXR.

Figures

Figure 1
Figure 1
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. fMRI: functional magnetic resonance imaging; RCT: randomized controlled trial.

Similar articles

Cited by

References

    1. Sanders JJ, Curtis JR, Tulsky JA. Achieving goal-concordant care: a conceptual model and approach to measuring serious illness communication and its impact. J Palliat Med. 2018 Mar;21(S2):S17–27. doi: 10.1089/jpm.2017.0459. https://europepmc.org/abstract/MED/29091522 - DOI - PMC - PubMed
    1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MS, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022 Feb 22;145(8):e153–639. doi: 10.1161/CIR.0000000000001052. https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001052?url_ver... - DOI - DOI - PubMed
    1. Kelley AS. Epidemiology of care for patients with serious illness. J Palliat Med. 2013 Jul;16(7):730–3. doi: 10.1089/jpm.2013.9498. https://europepmc.org/abstract/MED/23718871 - DOI - PMC - PubMed
    1. Kelley AS, Bollens-Lund E. Identifying the population with serious illness: the "denominator" challenge. J Palliat Med. 2018 Mar;21(S2):S7–16. doi: 10.1089/jpm.2017.0548. https://europepmc.org/abstract/MED/29125784 - DOI - PMC - PubMed
    1. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ. 2005 Apr 30;330(7498):1007–11. doi: 10.1136/bmj.330.7498.1007. https://europepmc.org/abstract/MED/15860828 330/7498/1007 - DOI - PMC - PubMed

Publication types

LinkOut - more resources